Methotrexate Market Segmentation:
Application Segment Analysis
The cancer treatment segment is likely to capture methotrexate market share of over 54.3% by 2035. The increasing cases of cancer are pushing the demand for methotrexate drugs for effective treatment. The World Health Organization (WHO) reveals that around 20 million new cancer cases were diagnosed in 2022. Also, the same source estimates that one in five individuals experience cancer growth in their lifetime. Manufacturers’ continuous focus on innovations is leading to the development of advanced and effective anti-cancer methotrexate solutions. For instance, in August 2024, STAQ Pharma announced the expansion of its oncology portfolio starting with methotrexate. The methotrexate solution is widely used for the treatment of pediatric cancer patients.
Formulation Segment Analysis
The tablet segment is expected to hold a dominating methotrexate market share throughout the projected period. Convenience and accurate dosage are prime factors driving the sales of methotrexate tablets. The pediatric and older patient demographics find tablets a more convenient form of administration than injections. The quick effect and cost-effectiveness are other aspects augmenting the demand for methotrexate tablets. Considering these drivers, manufacturers are more concentrated on the development of methotrexate tablets than other formulations. For instance, in August 2024, Elite Pharmaceuticals, Inc. announced the introduction of generic methotrexate sodium 2.5 mg tablets. These tablets are used for acute lymphoblastic leukemia treatment among adults.
Our in-depth analysis of the global methotrexate market includes the following segments:
|
Application |
|
|
Formulation |
|
|
Distribution Channel |
|
|
End use |
|
